CBD oil may soothe itch in kids with rare skin disease
NCT ID NCT05651607
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether cannabidiol (CBD) can reduce severe itching in 10 children with a rare genetic skin condition called epidermolysis bullosa. The children took CBD syrup three times a day for a month. Researchers measured itch, pain, sleep, and quality of life before and after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cannabidiol (CBD) oral solution
- What this could lead to
- If it works, CBD could offer a new way to relieve severe itching and improve quality of life for children with this rare skin condition.
- What could go wrong
- This is a very small, early-phase trial with only 10 children, so results may not apply to everyone. CBD may cause side effects, and the itch relief might not last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Nov 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Minor patient between 2 and 17 years and 10 months * Suffering from distrophic recessive epidermolysis bullosa * Patient weight less than or equal to 40 kg * With pruritus not relieved by conventional treatments with mean VAS greater than or equal to 4/10 the 3 days preceding inclusion * No change in treatment or care for at least one month * Consent of parents * Affiliated to social security Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients (Refined sesame oil, anhydrous ethanol, sucralose, strawberry flavor, includes benzyl alcohol) * Consumption of cannabis or cannabidiol * Severe renal impairment defined by GFR less than 29 ml/min * Moderate to severe hepatic impairment defined by a Child-Pugh B or C score or an AST and/or ALT level greater than 3 times normal and/or bilirubin more than 2 times normal * with clinically or ultrasound sign(s) of moderate to severe cardiac insufficiency, defined by LVEF less than 45% and stage II to IV of the NYHA classification * Taking a tricyclic antidepressant treatment with anti-H4 antihistamine action or a neurokinin-1 receptor antagonist in the previous month * Participating to an interventional research (category 1 or 2) * Modification of at least one background treatment in the previous month * Proven pregnancy or breastfeeding patient * Patient deprived of their liberty by decision of a judicial or administrative authority (Article L. 1121-6 of the Public Health Code)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dystrophic recessive epidermolysis bullosa are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.